Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Tesla Inc.'s eye-popping rally on Thursday after "a solid beat on the bottom and a minor miss on the top" for the third ...

Novo Nordisk is announcing the results of a recent Léger1 poll that has been conducted on its behalf, which found that four ...

Detailed price information for Innovator U.S. Equity Ultra Buffer ETF Apr (UAPR-A) from The Globe and Mail including charting and trades.